Skip to main content

Participate in a Trial

Start your journey

NCT03805789 | Phase 2 | Interventional

Acute-graft-versus-host Disease

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant

24 Sites
310 Participants
12 Years
NCT04672733 | Observational

Chronic Inflammatory Demyelinating Polyneuropathy

Hizentra® in Inflammatory Neuropathies - pHeNIx Study

23 Sites
100 Participants
18 Years
NCT05937581 | Phase 1 | Interventional

Complement Deficiencies

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

1 Sites
60 Participants
18 Years to 64 Years
NCT05086575 | Observational

Haemophilia B

Observatory of Patients With Haemophilia B Treated by IdElvion®

28 Sites
100 Participants
NCT06008938 | Observational

Hemophilia B

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

1 Sites
500 Participants
18 Years
NCT06003387 | Phase 3 | Interventional

Hemophilia B

Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

3 Sites
35 Participants
18 Years
NCT05819775 | Phase 3 | Interventional

Hereditary Angioedema (HAE)

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

11 Sites
20 Participants
2 Years to 11 Years
NCT05766839 | Phase 2 | Interventional


Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

6 Sites
36 Participants
to 11 Years
NCT05875961 | Phase 1 | Interventional

Influenza, Human

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

4 Sites
600 Participants
18 Years
NCT03684018 | Phase 4 | Interventional

Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Two Dose Levels of Privigen in Pediatric CIDP

6 Sites
30 Participants
2 Years to 17 Years
NCT05568888 | Phase 3 | Interventional

Traumatic Injury

Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

80 Sites
8000 Participants
15 Years